MDM2 Human shRNA Plasmid Kit (Locus ID 4193)
MDM2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector
|Product Name||MDM2 Human shRNA Plasmid Kit (Locus ID 4193)|
|Synonyms||ACTFS; hdm2; HDMX|
|Kit Components||MDM2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 4193). 5µg purified plasmid DNA per constructNon-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.|
|RefSeq||NM_001145336, NM_001145337, NM_001145339, NM_001145340, NM_001278462, NM_002392, NM_006878, NM_006879, NM_006880, NM_006881, NM_006882, XM_005268872, XM_006719399, XM_006719400|
|Summary||This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]|
|shRNA Design||These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service|
|Performance Guaranteed||OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at firstname.lastname@example.org. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
|The use of this RNAi has been cited in the following citations:|
Exonuclease-1 interacts with the transcriptional co-repressor KAP1
,El-Shemerly, M;Eid, W;Hess, D;Bologna, S;Gentili, C;Ferrari, S;,
EMILIN1–a4/a9 integrin interaction inhibits dermal fibroblast and keratinocyte proliferation
,Carla Danussi, Alessandra Petrucco, Bruna Wassermann, Eliana Pivetta, Teresa Maria Elisa Modica, Lisa Del Bel Belluz, Alfonso Colombatti, and Paola Spessotto,
J. Cell Biol., Oct 2011; 195: 131 - 145.